As Bristol Myers Squibb Co (BMY) Shares Rose, Shareholder Wellington Management Group Llp Increased Its Stake by $8.42 Billion

May 17, 2018 - By Brenda Gibbons

Bristol-Myers Squibb Company (NYSE:BMY) Corporate LogoDuring Q4 2017 the big money sentiment decreased to 0.94. That’s change of 0.09, from 2017Q3’s 1.03. 72 investors sold all, 526 reduced holdings as BMY ratio dived. 457 grew holdings while 106 funds amassed holdings. Funds hold 1.11 billion shares thus 0.48% more from 2017Q3’s 1.11 billion shares. 176,864 are owned by Willis Investment Counsel. Sit Invest Associates invested 0.01% of its capital in Bristol-Myers Squibb Company (NYSE:BMY). Regentatlantic Limited Liability Company holds 0.08% or 15,709 shs. Ballentine Ltd Com holds 0.04% or 11,943 shs in its capital. Nomura Asset Management Communication Ltd reported 263,785 shs or 0.19% of all its holdings. Mitsubishi Ufj Tru Banking, Japan-based fund reported 3.38 million shs. Villere St Denis J & Com has invested 0.02% in Bristol-Myers Squibb Company (NYSE:BMY). Perkins Coie Co has 0.09% invested in Bristol-Myers Squibb Company (NYSE:BMY). Quantitative Systematic Strategies Limited Liability Corp has invested 0.58% of its capital in Bristol-Myers Squibb Company (NYSE:BMY). Main Street Research Ltd has invested 0.28% in Bristol-Myers Squibb Company (NYSE:BMY). Windsor Capital Mngmt Limited Company reported 0.46% of its capital in Bristol-Myers Squibb Company (NYSE:BMY). Federated Invsts Pa, a Pennsylvania-based fund reported 335,414 shs. Stonebridge Cap Ltd holds 80,006 shs. Parnassus Investments Ca holds 0.67% or 2.80M shs in its capital. Eagleclaw Managment Ltd Com accumulated 10,222 shs.

BMY registered $163,963 net activity with 2 buys and 1 sale since December 12, 2017. On Tuesday, December 12 Lynch Thomas J. Jr. sold $335,172 worth of Bristol-Myers Squibb Company (NYSE:BMY). On Friday, December 15 4,000 shs were bought by Samuels Theodore R. II, worth $249,187.

Wellington Management Group Llp’s holdings in Bristol Myers Squibb Co (BMY) is upped by 5762516.82% based on its latest 2017Q4 regulatory filing with the SEC. 138.07 million shares were bought by Wellington Management Group Llp as the company’s stock rose 2.38% while stock markets declined. The institutional investor is holding 138.07M shares, compared to the 2,396 from the previous quarter. And the reported value of the major pharmaceuticals company is $8.46 billion for the 2017Q4. Bristol Myers Squibb Co has $85.36B market cap. The stock decreased 0.17% or $0.09 during the last trading session, hitting $52.21.Currently Bristol-Myers Squibb Company is uptrending after 11.37% change in last May 17, 2017. BMY has also 5.42M shares volume. BMY underperformed the S&P500 by 0.18%.

A portfolio of $452.59 billion is managed by Wellington Management Group Llp. As it’s reported in Securities and Exchange form the stake in Bank Of Nt Butterfield&Son L is reduced by 794,216 shares to 3.25 million shares. They are valued at $117.82M in 2017Q4. Wellington Management Group Llp has cut its stake in Scana Corp New (NYSE:SCG) and also reduced its holding in Las Vegas Sands Corp (NYSE:LVS) by 372,842 shares in the quarter, for a total of 3.82 million shares.

For more Bristol-Myers Squibb Company (NYSE:BMY) news released briefly go to: Fool.com, Bizjournals.com, Seekingalpha.com, Streetinsider.com or Seekingalpha.com. The titles are as follows: “Why Bristol-Myers Squibb Stock Crashed in April” released on May 09, 2018, “How Bristol-Myers Squibb’s new Peninsula digs boost its battle to beat cancer” on May 01, 2018, “Don’t Buy L Brands – Cramer’s Lightning Round (5/15/18)” with a publish date: May 16, 2018, “Bristol-Myers Squibb (BMY) Highlights Breadth of Immuno-Oncology–Based Combination Research and Commitment …” and the last “Ziopharm, Trump’s Drug Pricing Plan And The Future Of Expensive Drug Development” with publication date: May 15, 2018.

Bristol-Myers Squibb Company (NYSE:BMY) Ratings Coverage

Total analysts of 11 have positions in Bristol Myers (NYSE:BMY) as follows: 4 rated it a “Buy”, 0 with “Sell” and 7 with “Hold”. The positive are 36%. The firm has $78.0 highest while $47 is the lowest price target. The average target $65.56 is 25.57% above the last ($52.21) price. Since February 6, 2018 according to StockzIntelligence Inc Bristol Myers has 17 analyst reports. On Friday, April 13 Jefferies maintained Bristol-Myers Squibb Company (NYSE:BMY) with “Hold” rating. On Tuesday, April 17 Guggenheim maintained the shares of BMY in report with “Buy” rating. In Thursday, February 15 report Morgan Stanley upgraded the stock to “Overweight” rating. On Tuesday, April 17 the firm has “Equal-Weight” rating given by Morgan Stanley. On Tuesday, February 6 the rating was maintained by BMO Capital Markets with “Underperform”. On Friday, April 20 Cowen & Co maintained Bristol-Myers Squibb Company (NYSE:BMY) rating. Cowen & Co has “Hold” rating and $6000 target. On Friday, April 27 the firm has “Market Perform” rating given by BMO Capital Markets. On Wednesday, February 28 the stock has “Hold” rating by DZ Bank. On Monday, February 26 Jefferies maintained Bristol-Myers Squibb Company (NYSE:BMY) rating. Jefferies has “Hold” rating and $72.0 target. On Tuesday, April 17 the firm has “Neutral” rating given by Bank of America.

Bristol-Myers Squibb Company (NYSE:BMY) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: